Letter to Editor

Low pH preconditioned amniotic epithelial cells for stem cell therapy of cancer

Hassan Niknejad¹,²*, Ghasem Yazdanpanah¹, Mona Kakavand², Yasaman Lavaie²

¹. Department of Tissue Engineering and Regenerative Medicine, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
². Nanomedicine and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Amniotic epithelial cells (AECs) possess unique characteristics, which make them a suitable source for cell-based therapeutic strategies. AECs have stem cell properties with low-immunogenicity (due to expressing HLA-G molecule and absence of MHC class I and II antigens) and no ethical problems, as well as availability in sufficient numbers, which can be obtained from a placenta. We have recently shown that the AECs have anti-cancer properties due to inhibition of angiogenesis, induction of apoptosis and cell cycle arrest probably through inhibition of HSP90. Since the viability of AECs must be improved after in vivo administration in acidic microenvironment of tumor, we clarify here that low pH preconditioning of AECs would lead to more survival of implanted cells in tumor site as well as improved functional outcomes.

Introduction

Amniotic epithelial cells (AECs), the innermost cell layer of placenta, are in direct contact with amniotic fluid during pregnancy (Peirovi et al., 2012). The AECs have low immunogenicity, anti-fibrotic and anti-bacterial properties (Tehrani et al., 2013; Kakavand et al., 2015), as well as stem cell characteristics (Niknejad et al., 2013a), which make them suitable for using in a variety of clinical fields. We have shown recently that amniotic membrane and amniotic cells have anti-cancer property (Niknejad et al., 2013b; Niknejad et al., 2016). AECs possess anti-tumor characteristics due to induction of apoptosis and cell cycle arrest in cancer cells and also inhibition of angiogenesis (Seo et al., 2008; Niknejad et al., 2014; Niknejad and Yazdanpanah, 2014). Soluble factors secreted from cultured AECs induce apoptosis in cancer cells (Niknejad et al., 2014). Inhibition of heat shock protein-90 is probably responsible for anti-cancer property of the AECs (Niknejad et al., 2013d). In addition, amniotic cells secret anti-neoplastic soluble factors such as interferon-γ, interleukin-2, 3, 4, and 8, tumor necrosis factor-β, transforming growth factor-β, macrophage colony-stimulating factor, granulocyte macrophage colony-stimulating factor, and granulocyte chemotactic protein (GCP-2) (Niknejad et al., 2012; Mamede et al., 2014). Furthermore, the cells cycle is arrested in G1/S
AECs produce and release some chemicals, which inhibit capillary formation and decrease both the number of vessel sprout and vessel length. AECs express some anti-angiogenic factors including thrombospondin-1, endostatin and heparin sulfate proteoglycan (Yazdanpanah et al., 2015). Also, amniotic cells contain all four tissue inhibitors of metalloproteases (TIMP-1, -2, -3 and -4), which have potent anti-angiogenic effect (Niknejad et al., 2013c). Based on these evidences, AECs have been targeted for cell-based therapy of cancer.

The successful employment of stem cells for cell replacement therapies has been limited by poor survival rate of the cells following implantation. Significant decrease of cell survival and induction of apoptosis occur following injection of the cells and reduce the effectiveness of stem cell therapy, with some estimating about 90% cell loss within 24 hours of implantation (Abraham and Gerstenblith, 2007). Several approaches have been developed to overcome this problem, in which cellular preconditioning and reprogramming prior to implantation into pathological sites (using physical, chemical, genetic, and pharmacological manipulation of the cells) have demonstrated promising results that “prime” the stem cells to the “state of readiness” (Haider and Ashraf, 2010). Preconditioning stem cells prior to implantation to diseased or damaged tissue has been shown to increase implanted cell survival as well as to improve functional outcomes.

Acidic pH is a major characteristic of tumor microenvironment, which could affect survival of the cells transplanted for inhibition of cancer progression. Since AECs have been targeted for cell therapy of cancer, we suggest here that low pH preconditioning of amniotic cells could survive and inhibit apoptosis of cells after injection in tumor microenvironment. The acidic preconditioning protocols are depending on the

**Fig. 1.** Low pH preconditioning of the amniotic epithelial cells leads to more survival of these cells after injection into tumor microenvironment. Low pH (high concentration of H+) activates G-protein coupled receptors (GPCRs). GPCRs activate adenyl cyclase (AC) that produces cAMP with further activation of PI3K/Akt pathway. GPCRs also activate ERK1/2 pathway. PI3K/Akt and ERK1/2 pathways lead to transcription of genes associated with improvement in survival and inhibition of apoptosis. AECs with prior preconditioning secrete anti-cancer soluble factors in injected tumor site, which results in induction of apoptosis in tumor cells and inhibition of angiogenesis.
Preconditioned amnion cells for cancer therapy

Physiol Pharmacol 20 (2016) 1-4


D’Atri LP, Etulain J, Romaniuk MA, Torres O, Negrotto S, Schattner M. The low viability of human cd34+ cells under acidic conditions is improved by exposure to thrombopoietin, stem cell factor, interleukin-3, or increased cyclic adenosine monophosphate levels. Transfusion 2011; 51: 1784-95.


References


Cencioni C, Melchiona R, Straino S, Romani M,


